An Improved qFibrosis Algorithm for Precise Screening and Enrollment into Non-Alcoholic Steatohepatitis (NASH) Clinical Trials.

Wei Qiang LeowPierre BedossaFeng LiuLai WeiKiat-Hon LimWei-Keat WanYayun RenPik-Eu Jason ChangChee-Kiat TanAileen WeeGeorge Boon-Bee Goh

Published in: Diagnostics (Basel, Switzerland) (2020)

The refined qFibrosis algorithm incorporated 26 novel parameters that showed a good discriminatory ability for NASH fibrosis stage 1 and 2 cases, representing an invaluable assistive tool for in-house pathologists when screening patients for NASH clinical trials.

Keyphrases

clinical trial
end stage renal disease
machine learning
deep learning
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
prognostic factors
healthcare
open label
liver fibrosis
phase iii